Reported 21 days ago
Hims & Hers Health experienced a significant increase in its share price following the announcement of better-than-anticipated third quarter revenue, with a year-over-year growth of 77% and a profit boosted by tax benefits and high demand for GLP-1 weight-loss drugs. CFO Yemi Okupe detailed the company's performance and addressed potential challenges from Eli Lilly and Novo Nordisk's weight-loss medications, stating that while shortages are ongoing, consumer feedback indicates a strong demand for their services.
Source: YAHOO